Table 2.
Effects of first greater occipital nerve injection in 159 chronic headache patients with available follow-up
| Improvement from injection | n = 105 P < 0.001 | 66% |
|---|---|---|
| Duration of improvement (weeks) | 9.3 ± 4.3 | |
| Benefit per HA diagnosis (n; %) | ||
| CM | 70 | 69% |
| CMwA | 15 | 63% |
| Total migraine | 85 | 68% |
| NDPH | 13 | 59% |
| CH | 3 | 100% |
| HC | 0 | 0% |
| SUNCT/SUNA | 1 | 50% |
| Total TAC | 4 | 67% |
| TTH | 1 | 100% |
| Secondary HA | 2 | 50% |
| Sustained HA freedom (>3 weeks) | 17 | 16% |
| CM | 11 | 16% |
| CMwA | 2 (one brainstem) | 13% |
| Total migraine | 13 | 10% of total migraine |
| NDPH | 2 | 15%, 9% of total NDPH |
| CH | 1 | 33% |
| SUNCT | 1 | 100% |
| Total TAC | 2 | 33% of total TAC |
| Side effects | 13 | 8% |
| Worsened HA int/freq for up to 5 weeks | 6 (with no improvement) | |
| Worsened HA int/freq for up to 10 days | 5 (with improvement) | |
| Soreness | 1 | |
| Reaction to sedative | 1 | |